Advertisement
Advertisement
-
Money /

Markets & Investing

The logo of Sino Biopharmaceutical is seen on a building in Beijing, April 22, 2021. Photo: VCG via Getty Images
Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

IPO

HSBC chairman floats ‘IPO connect’ for Hong Kong, Shenzhen listings

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
Hong Kong stock market

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.

Mainland China

China’s copper crash: from investment fad to scrap in a month

A brief speculative frenzy amid skyrocketing gold and silver prices leaves some retail investors holding shiny kilogram bars they can’t sell.

Advertisement
Advertisement
Advertisement
China stock market

US investors increase buying of Hong Kong, mainland Chinese stocks

American investors bought US$15 billion of Hong Kong and mainland stocks in 2025, as buying picked up steam through the year.

A man walks on illuminated stairs at M+ Museum in West Kowloon as Hong Kong’s skyline is seen in a reflection on May 28, 2025. Photo: Eugene Lee
A man walks on illuminated stairs at M+ Museum in West Kowloon as Hong Kong’s skyline is seen in a reflection on May 28, 2025. Photo: Eugene Lee
Banking & finance

Standard Chartered’s 2025 profit jumps 16% buoyed by wealth management growth

The London-based bank’s underlying pre-tax profit stood at US$7.9 billion last year, versus a gain of US$6.8 billion in 2024.

Hong Kong stock market

Hong Kong stocks retreat on AI worries, China markets rally in Year of the Horse

Tech heavyweights drag Hong Kong stocks lower as investors fret over AI disruption following Wall Street’s decline.

Hong Kong stock market

Why is the Hang Seng Tech Index underperforming while AI shares soar?

The gauge has fallen 5.5 per cent this year, while newly listed AI firms Zhipu AI, MiniMax and Beijing Haizhi are up at least fivefold.

The Hang Seng Tech Index, which includes Tencent Holdings, Alibaba Group Holding and Meituan, has fallen 5.5 per cent this year. Photo: Jonathan Wong
Made in China 2025

After boost from viral dance challenge, Chinese medicine firm’s shares languish

Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.

The combined daily production capacity of ibuprofen and paracetamol in China surged fourfold to 202 million tablets by late December 2022. Photo: Shutterstock
The combined daily production capacity of ibuprofen and paracetamol in China surged fourfold to 202 million tablets by late December 2022. Photo: Shutterstock
Gold in Hong Kong

Hong Kong stocks and gold start the Year of the Horse on a mixed note

The Hang Seng Index fell 1.1 per cent on the first day of trading of the new year, while local gold prices rose 0.6 per cent.

Hong Kong stock market

Hong Kong stocks fall as market reopens after 3-day Lunar New Year holiday

Tech heavyweights Alibaba, Baidu and Kuaishou drop as trading commences in the Year of the Horse.

Gold in Hong Kong

Gold’s volatile run set to continue as investors eye next breakout

Investors are like crocodiles waiting to strike, Jupiter says, as bullion eyes new highs amid continuing geopolitical and policy tension.

With physical bullion in short supply, analysts see mining companies as a more efficient way to gain exposure, offering potentially higher returns. Photo: AFP
Banking & finance

Can Hong Kong’s MPF members repeat record gains in Year of the Horse?

Volatility looms in the Year of the Horse, analysts forecast, after the Year of the Snake delivered estimated earnings of US$32 billion.

People walk during lunch hour in Central, Hong Kong. In the previous Year of the Horse in 2014, MPF members earned 2.2 per cent, while in 2002 they lost 0.4 per cent. Photo: Karma Lo
People walk during lunch hour in Central, Hong Kong. In the previous Year of the Horse in 2014, MPF members earned 2.2 per cent, while in 2002 they lost 0.4 per cent. Photo: Karma Lo
Hong Kong stock market

Hong Kong stocks rise to wrap up best lunar-year performance in eight years

As market closes for Lunar New Year, benchmark hits 32 per cent gain since the Year of the Snake began in January 2025.

Hong Kong stock market

Korean investors pour US$92.5 million into Hong Kong AI, tech stocks

Return to mainland equities bends towards start-ups and ETFs, versus earlier focus on bellwether, large-cap names.

Advertisement
Advertisement
Advertisement
IPO

Shenzhen-listed Unisplendour abandons plan to raise funds in Hong Kong

The Tsinghua Holdings arm, however, will raise US$800 million via a private share placement on Shenzhen exchange.

Unisplendour was expected to raise US$1 billion from its Hong Kong share sale this year. Photo: Reuters
Unisplendour was expected to raise US$1 billion from its Hong Kong share sale this year. Photo: Reuters
China stock market

Index compiler MSCI tilts towards Chinese tech stocks in latest revamp

A net 21 stocks were added to the MSCI China Index, including SenseTime, Pony.ai and Hesai Technology.

Made in China 2025

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

Hong Kong stock market

Hong Kong stocks rise as positive holiday bias sets in ahead of Lunar New Year

Southbound net inflows reflect investor optimism about Hong Kong stocks after the holiday, analyst says.

Bull statues look out over Exchange Square, where Hong Kong’s bourse operator is headquartered, on February 3, 2026. Photo: Reuters
Made in China 2025

Chinese healthcare firms expand overseas to support growing expat community

Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.

Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

Banking & finance

China slashes wait times for loss-making tech firms seeking refinancing, fundraising

Three of China’s stock exchanges have relaxed fundraising time thresholds on listed tech companies as Beijing pushes for self-reliance.

videocam
Made in China 2025

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.

A view of the Shanghai facility of Fosun Pharma’s biopharma unit Henlius. Photo: Handout
Help preserve 120 years of quality journalism.
SUPPORT NOW